Quality of life of postmenopausal women with teriparatide, denosumab and alendronate: One-year prospective study with a propensity score-matched comparison

Quality of life of postmenopausal women with teriparatide, denosumab and alendronate: One-year prospective study with a propensity score-matched comparison

Background/purpose: To evaluate and compare the effects of parathyroid hormone analogues, receptor activators of nuclear factor kappa-B ligand inhibitors and bisphosphonates on the quality of life of postmenopausal women. Methods: A prospective observational study of 23 matched postmenopausal women...

Full description

Bibliographic Details
Main Authors:	Pun Yuet Lam, Prudence Wing Hang Cheung, Sin Ting Lau, Jason Pui Yin Cheung
Format:	Article
Language:	English
Published:	SAGE Publishing 2023-06-01
Series:	Journal of Orthopaedics, Trauma and Rehabilitation
Online Access:	https://doi.org/10.1177/22104917221136282

Similar Items

Efficacy of the Combination of Teriparatide and Denosumab in the Treatment of Postmenopausal Osteoporosis: A Meta-Analysis
by: Yang Sun, et al.
Published: (2022-05-01)

A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis
by: M Stevenson, et al.
Published: (2005-06-01)

Cost‐Effectiveness of Sequential Teriparatide/Alendronate Versus Alendronate‐Alone Strategies in High‐Risk Osteoporotic Women in the US: Analyzing the Impact of Generic/Biosimilar Teriparatide
by: Takahiro Mori, et al.
Published: (2019-11-01)

Reduction in fracture rates with Denosumab compared to Alendronate in treatment naïve patients: a propensity-matched ‘real world’ cohort and instrumental variable analysis.
by: Khalid, S, et al.
Published: (2017)

Efficacy and safety of denosumab and teriparatide versus oral bisphosphonates to treat postmenopausal osteoporosis: a systematic review and meta-analysis
by: Jia Yang, et al.
Published: (2024-09-01)

Effect of Teriparatide in Postmenopausal Women with Osteoporosis
by: Masoud Shayestehazar, et al.
Published: (2018-12-01)

No evidence for alteration in early secondary mineralization by either alendronate, teriparatide or combination of both in transiliac bone biopsy samples from postmenopausal osteoporotic patients
by: Barbara M. Misof, et al.
Published: (2020-06-01)

Impact of Teriparatide and Denosumab on Clinical and Radiographic Outcomes in Osteoporotic Vertebral Compression Fractures
by: Byung-Taek Kwon, et al.
Published: (2024-08-01)

Denosumab, teriparatide and bisphosphonates for glucocorticoid-induced osteoporosis: a Bayesian network meta-analysis
by: Liang Dong, et al.
Published: (2024-01-01)

Effects of Teriparatide and Alendronate on Functional Recovery from Spinal Cord Injury and Postinjury Bone Loss
by: Shuai Wang, et al.
Published: (2025-02-01)

Teriparatide treatment for postmenopausal women with sacral insufficiency fracture
by: Young-Hoon Kim
Published: (2023-06-01)

Preoperative denosumab treatment in patients with giant cell bone tumors in limbs: A retrospective study using propensity score matching
by: Yongfu Huang, et al.
Published: (2023-06-01)

Reply on “teriparatide treatment for postmenopausal women with sacral insufficiency fracture”
by: Yao-Chun Yang, et al.
Published: (2023-06-01)

Denosumab treatment and infection risks in patients with osteoporosis: propensity score matching analysis of a national-wide population-based cohort study
by: Shih-Ting Huang, et al.
Published: (2023-05-01)

Predictive factors for successful non-operative treatment and achieving MCID improvement in health-related quality of life in adult spinal deformity
by: Jason Pui Yin Cheung, et al.
Published: (2022-08-01)

Efficacy of zoledronate, denosumab or teriparatide in postmenopausal women with type 2 diabetes mellitus at high risk of fragility fractures: protocol of an open, blinded endpoint randomized controlled pilot trial
by: Trupti Nagendra Prasad, et al.
Published: (2023-10-01)

Head to head comparison of the propensity score and the high-dimensional propensity score matching methods
by: Jason R. Guertin, et al.
Published: (2016-02-01)

Longitudinal comparison of direct medical cost, radiological and health-related quality of life treatment outcomes between traditional growing rods and magnetically controlled growing rods from preoperative to maturity
by: Prudence Wing Hang Cheung, et al.
Published: (2022-08-01)

Comparison of risk of osteoporotic fracture in Denosumab vs Alendronate treatment within 3 years of initiation
by: Pedersen, AB, et al.
Published: (2019)

Effect of Denosumab or Alendronate on Vascular Calcification: Secondary Analysis of SALTIRE2 Randomized Controlled Trial
by: Jolien Geers, et al.
Published: (2024-09-01)

Comparison of teriparatide and bisphosphonate in the treatment of postmenopausal osteoporosis: A meta-analysis
by: Yudong Li, et al.
Published: (2025-01-01)

Comparative analysis of denosumab, romosozumab, and teriparatide effects on bone density and structural integrity in osteoporotic vertebral compression fractures
by: T. Goh, et al.
Published: (2024-01-01)

Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain
by: Darbà J, et al.
Published: (2015-02-01)

Denosumab – a new medication in the treatment of postmenopausal osteoporosis
by: Radosław Słopień, et al.
Published: (2017-10-01)

Clinical efficacy of denosumab, teriparatide, and oral bisphosphonates in the prevention of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis
by: Chuanjian Yuan, et al.
Published: (2023-06-01)

The Effect of Once-Weekly 70 Mg Alendronate Versus Once-Daily 10 Mg Alendronate in the Treatment of Postmenopausal Osteoporosis
by: İlker Çorapçı, et al.
Published: (2004-03-01)

Analyzing the factors associated with efficacy among teriparatide treatment in postmenopausal women with osteoporosis
by: Meng Kong, et al.
Published: (2024-02-01)

The Effect of Alendronate Treatment on Bone Density and Bone Markers in Postmenopausal Osteoporosis
by: S. Akı, et al.
Published: (2002-03-01)

APSS-ASJ Best Clinical Research Award: Predictability of Curve Progression in Adolescent Idiopathic Scoliosis Using the Distal Radius and Ulna Classification
by: Jason Pui Yin Cheung, et al.
Published: (2018-04-01)

The efficiency and safety of alendronate versus teriparatide for treatment glucocorticoid-induced osteoporosis: A meta-analysis and systematic review of randomized controlled trials.
by: Zhi-Ming Liu, et al.
Published: (2022-01-01)

Propensity Score Matching Analysis for Alcohol‐Related Liver Disease
by: Fangfang Duan, et al.
Published: (2025-01-01)

Impact of teriparatide therapy in Indian postmenopausal women with osteoporosis with regard to DXA-derived parameters
by: Nandipati Venkata Sandeep, et al.
Published: (2022-07-01)

Traditional growing rod versus magnetically controlled growing rod for treatment of early onset scoliosis: Cost analysis from implantation till skeletal maturity
by: Carlos King Ho Wong, et al.
Published: (2017-05-01)

Risk of osteoporotic fractures in new users of denosumab compared with new users of alendronate: A Danish populationbased cohort study
by: Pedersen, AB, et al.
Published: (2018)

Why Propensity Scores Should Not Be Used for Matching
by: King, Gary, et al.
Published: (2020)

Propensity-score matching: a clinician’s guide
by: Andrew D Althouse
Published: (2016-06-01)

Denosumab compared to bisphosphonates to treat postmenopausal osteoporosis: a meta-analysis
by: Jiaqi Wu, et al.
Published: (2018-08-01)

Effects of Alendronate and Raloxifene on Bone Density and Bone Turnover Markers in Postmenopausal Women
by: Ebru Zülfikaroğlu, et al.
Published: (2011-04-01)

Two Years of Alendronate and Calcitonin Treatments for Osteoporosis in Postmenopausal Women - Original Investigation
by: Gülcan Gürer, et al.
Published: (2006-03-01)

Effects of Alendronate, Calcitonin and Raloxifene Used in the Treatment of Postmenopausal Osteoporosis On Serum No Levels
by: Saliha Karatay, et al.
Published: (2005-03-01)